Results presented today at the 162nd American Psychiatric Association (APA) congress in San Francisco, CA, demonstrated the efficacy and tolerability of SEROQUEL® (quetiapine fumarate) for treating depressive episodes in bipolar disorder, including the difficult-to-treat bipolar II patient population.1,2 The data are from combined analyses of four large-scale clinical trials to examine SEROQUEL as a treatment for depressive episodes associated with bipolar I and II disorders.
Popularity: unranked [?]
Related posts:
- Astrazeneca Submits Seroquel XR For The Treatment Of Bipolar Mania And Bipolar Depression, And Seroquel(R) For The Treatment Of Bipolar Depression
- FDA Approves AstraZeneca’s SEROQUEL(R) For Bipolar Depression Treatment
- First Large-Scale Study Addressing Augmentation Treatment For Resistant Major Depressive Disorder
- FDA Approves AstraZeneca’s Seroquel® For Bipolar Depression Treatment
- SEROQUEL Exhibits Distinct Mechanism Of Action And Reduces The Risk Of A Mood Event In Bipolar I Disorder
Comments
No Responses to “Combined Data From Four Large-Scale Studies Demonstrate The Efficacy And Tolerability Of Seroquel In Bipolar Depression”